Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...

GET MORE AI-GENERATED SIGNALS: September 19, 2024, 20:16 pm ET, BY Jeff W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

Shares of GSK PLC GSK inched up 0.73% to £16.64 Monday, on what proved to be an all-around great trading session for the ...

The revenue for GSK-3739937 is expected to reach an annual total of $7 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...

PITTSBURGH – The Nationals got the job done in Game 1 of today’s doubleheader against the Pirates. DJ Herz tossed five no-hit innings before departing with his pitch count at 87. Dylan Crews ...

Proactive Investors - GSK PLC (LON:GSK) announced positive results from a Phase III clinical trial, MATINEE, evaluating Nucala (mepolizumab) in chronic obstructive pulmonary disease (COPD). The trial ...

Nucala is currently not indicated for COPD anywhere in the world. The drug contributed 6% to GSK’s 2023 sales, with revenue of 1.65 billion pounds, up 18% at CER year over year. Ohtuvayre is the ...